ACK1 Inhibitors
3 drugsAbout ACK1
ACK1, or Activated CDC42 Kinase 1, is a non-receptor tyrosine kinase involved in cell growth, survival, and migration. Dysregulation of these processes makes ACK1 a compelling oncology target.
While there is no genetic evidence directly linking ACK1 to specific diseases, its role in cancer-related cellular processes supports therapeutic intervention. Two FDA-approved drugs targeting ACK1 highlight its clinical relevance.
ACK1 is targeted by two FDA-approved small molecule drugs: ZELBORAF (Roche) and TAGRISSO (AstraZeneca). These drugs are approved for oncology and other therapeutic areas.
Top ACK1 Drugs
The competitive landscape consists of Roche and AstraZeneca, each with approved ACK1-targeting drugs.
The limited number of companies indicates a relatively unconcentrated market with potential entry points.
ACK1 Drug Modality Landscape
Modalities
Routes of Administration
ACK1 is amenable to small molecule drugs, with oral options available for convenient dosing.
The lack of diverse modalities suggests an opportunity to explore antibody or PROTAC-based ACK1 therapeutics.
ACK1 Clinical Trials 330 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on ACK1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 118 | 51 | 26 | 40 | 66% |
| Phase 2 | 160 | 46 | 22 | 92 | 68% |
| Phase 3 | 41 | 7 | 3 | 31 | 70% |
| Phase 4 | 11 | 5 | 1 | 5 | 83% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved ACK1 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting ACK1. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
ACK1 Drug Approval Timeline (2011 - 2018)
The first ACK1-targeting drug was approved in 2011 (ZELBORAF), with the most recent approval in 2015 (TAGRISSO).
The relatively short approval span suggests a potentially maturing target with limited recent innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 168 (54 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on ACK1. A trial counts if an approved drug acting on ACK1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.